Related Experiment Videos
Preclinical characterization of a new pasteurized monoclonal antibody purified factor VIIIC
M E Hrinda1, F Feldman, A B Schreiber
1Biotechnology Department, Rorer Central Research, King of Prussia, PA 19406.
Seminars in Hematology
|April 1, 1990
Abstract:
The treatment of hemophilia A patients has progressed in the last 30 years. The development of more pure factor VIII concentrates has been encouraged by the appearance of the human immunodeficiency virus in blood supply. Monoclate was the first essentially pure form of factor VIII available for hemophilia therapy. The liquid pasteurized form of Monoclate represents a new standard for therapy that attempts to eliminate a broad spectrum of viral content in factor VIII preparations.